Cumberland Pharmaceuticals (CPIX) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 243.47% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 1,034.67% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 63.59% |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | -560.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -560.36% |
| Mar 31, 2026 | -90.07% |
| Dec 31, 2025 | -99.84% |
| Sep 30, 2025 | -60.64% |
| Jun 30, 2025 | 198.61% |
| Mar 31, 2025 | 282.46% |
| Dec 31, 2024 | 83.12% |
| Sep 30, 2024 | -61.55% |
| Jun 30, 2024 | -116.34% |
| Mar 31, 2024 | -50.66% |
| Dec 31, 2023 | -71.41% |
| Sep 30, 2023 | -53.08% |
| Jun 30, 2023 | 124.64% |
| Mar 31, 2023 | -842.34% |
| Dec 31, 2022 | 85.64% |
| Sep 30, 2022 | 2,683.48% |
| Jun 30, 2022 | -13.66% |
| Mar 31, 2022 | -108.43% |
| Dec 31, 2021 | 129.49% |
| Sep 30, 2021 | -111.90% |